Latest News - Ortho Dermatologics

Wednesday, November 07, 2018

Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasis

Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final appr…

Read the full story

Tuesday, October 30, 2018

Ortho Dermatologics' Altreno Now Available in the US

Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available…

Read the full story

Thursday, October 11, 2018

Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acne

Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) …

Read the full story

Monday, October 08, 2018

Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis

The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion …

Read the full story

Tuesday, October 02, 2018

Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials

Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…

Read the full story

Wednesday, August 29, 2018

FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasis

The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis.…

Read the full story

Friday, August 24, 2018

FDA Nod for Ortho Derm’s Acne Lotion Altreno

The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Ortho Dermatologic’s Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in p…

Read the full story

Thursday, August 16, 2018

Ortho Dermatologics Resubmits NDA for Duobrii Lotion

Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; …

Read the full story

Wednesday, August 08, 2018

Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipients

Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students w…

Read the full story

Monday, June 18, 2018

Valeant: FDA Issues Complete Response Letter for Duobrii

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA regarding the company's New Drug Application …

Read the full story

Friday, May 11, 2018

Valeant is Becoming Bausch Health Companies, Inc.

Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on the strong brand equity of the company’s businesses a…

Read the full story

Monday, April 09, 2018

Ortho Dermatologics’ DUOBRII Improves Psoriasis Symptoms As Early As Two Weeks

DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy o…

Read the full story

Thursday, March 01, 2018

Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2018 Aspire Higher Scholarship Program

Ortho Dermatologics is accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will …

Read the full story

Friday, February 16, 2018

Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis

Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities …

Read the full story

Wednesday, February 14, 2018

FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment

The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved…

Read the full story
Load More